Program
camoteskimab
Also written as “MEDI2338”, “Camoteskimab” and “AEVI-007”.
Its studies are mostly in Dermatitis, Atopic · Multiple Myeloma · Still's Disease, Adult-Onset · Pulmonary Disease, Chronic Obstructive, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Apollo Therapeutics | 31 open or running | phase 2since Apr 9, 2024 | Feb 9, 2021 | Oct 31, 2027phase 2 · NCT07599813 |
| AstraZeneca | 10 open or running | phase 1since Mar 23, 2011 | Mar 23, 2011 | none ahead |
| Avalo Therapeutics | 10 open or running | phase 1since Dec 1, 2020 | Dec 1, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 23, 2011First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveNew to AstraZenecaAstraZeneca · NCT01322594 · 31 enrolled · South Africa, United Kingdom
- Dec 1, 2020Avalo Therapeutics's first study: phase 1 study in Multiple MyelomaNew to Avalo TherapeuticsAvalo Therapeutics · NCT04671251 · 13 enrolled · United States
- Feb 9, 2021Apollo Therapeutics's first study: phase 1 study in Still's Disease, Adult-OnsetNew to Apollo TherapeuticsApollo Therapeutics · NCT04752371 · 5 enrolled · United States, Belgium, Poland and more
- Apr 9, 2024Phase 2 study in Dermatitis, AtopicApollo Therapeutics · NCT06436183 · 62 enrolled · United States, Canada
- May 15, 2026Phase 2 study in Dermatitis, AtopicApollo Therapeutics · NCT07599813 · 280 planned · United States, Bulgaria, Canada and more
Ahead
- Oct 31, 2027Primary completion: phase 2 study in Dermatitis, AtopicApollo Therapeutics · NCT07599813
TargetBeta
“A human immunoglobulin G1 (IgG1) monoclonal antibody against the pro-inflammatory cytokine interleukin-18 (IL-18), ”NCIt, by rule
“Interleukin-18 cross-linking agent”ChEMBL 37, by rule
Other programs on IL18
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| aletekitugrule | GlaxoSmithKline | phase 2 | 9 |
| arumakimig | Novartis | phase 2 | 7 |
| GHZ339 | Novartis | phase 2 | 1 |
| BLN-481rule | beeline-medicines-corporation | phase 1 | 1 |
| GSK4528287 | GlaxoSmithKline | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07599813Dermatitis, Atopic · United States, Bulgaria, Canada and more | 2 | Recruiting | Apollo Therapeutics | Oct 31, 2027 | 280 |
| NCT06436183Dermatitis, Atopic · United States, Canada | 2 | Completed | Apollo Therapeutics | Mar 26, 2025 | 62 |
| NCT04752371Still's Disease, Adult-Onset · United States, Belgium, Poland and more | 1 | Terminated | Apollo Therapeutics | May 24, 2022 | 5 |
| NCT04671251Multiple Myeloma · United States | 1 | Completed | Avalo Therapeutics | Mar 30, 2022 | 13 |
| NCT01322594Pulmonary Disease, Chronic Obstructive · South Africa, United Kingdom | 1 | Completed | AstraZeneca | Nov 2011 | 31 |
How it is read
Names in the registry
- “MEDI2338”, 5 entries
- “Camoteskimab”, 2 entries
- “AEVI-007”, 1 entry
- “Camoteskimab (CERC-007, AVTX-007, AEVI-007)”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 2 studies
- Multiple Myeloma, 1 study
- Still's Disease, Adult-Onset, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.